Med-Tech CEO’s turn to Emerging Markets for Double-Digit Growth

By Daniel R. Matlis

Med-Tech Companies are poised to capitalize on global opportunities; however, they must balance the risks and rewards of globalization. When Axendia’s research team surveyed Med-Tech executives we found that:Global-Innovation

  • 73% expect an increasing rate of new product introductions in emerging markets
  • 72% are globalizing to improve the rate of product innovation
  • 65% see the global regulatory environment as the top business threat
  • 55% are globalizing to speed up time-to-market

But you don’t have to take our word for it.  CEOs from leading Med-Tech companies are turning to emerging markets for double digit growth. Continue reading


Siemens’ Acquisition of Camstar Could Help Med-Tech Companies Close the Loop on Product Quality

By Daniel R. Matlis

Siemens’ acquisition of Camstar could help Medical Technology (Med-Tech) companies improve product quality by providing integrated solutions to manage Medical Devices across the Total Product Life Cycle (TPLC). The Camstar acquisition builds on Siemens’ industrial digitalization strategy by broadening its integrated product development and production automation. Continue reading

Image courtesy of Siemens

J&J – Siemens Collaborate on Personalized Medical Device Platform

By Daniel R. Matlis

Modern Healthcare is shifting to personalized care tailored to each patient’s anatomy, therapeutic regimen and expectations. As a result, Med-Tech companies are seeking new ways to develop, design and manufacture more personalized devices that improve patient outcomes while increasing quality of care and reducing Healthcare costs.

To address this need, Siemens and Johnson & Johnson’s DePuy Synthes Joint Reconstruction division leveraged the Personalized Product Innovation platform to develop the TRUMATCH® Personalized Solutions. Continue reading

Picture courtesy ofIBM

IBM puts Watson to work at Johnson & Johnson and Sanofi R&D

By Ellyn McMullin, Research Associate, Axendia, Inc.

Three years after its victory on the TV quiz show Jeopardy! IBM Watson has evolved to represent a new era of computing. Today, Watson is no longer just the world’s most famous game-playing computer. IBM has put Watson to work in various industries. In healthcare, IBM is co-developing an application with Memorial Sloan-Kettering Cancer Center, and partnering with WellPoint, the University of Texas MD Anderson Cancer Center, and the Cleveland Clinic Lerner College of Medicine.
IBM announced that it is putting Watson to work in Pharma R&D at Johnson & Johnson and Sanofi. Continue reading